Effect of Metformin on ABCB1 and AMPK Expression in Adolescents With Newly Diagnosed Acute Lymphoblastic Leukemia
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
Acute lymphoblastic leukemia, is the most frequent cancer in children and adolescents. Some
genes have been described to produce drug resistance, as ABCB1 probably by lack of activation
of AMPK. Some manuscripts have shown that metformin has antitumoral activity, mainly by
activation of AMPK.
This is an experimental one center trial, that pretend analyze the effect of metformin at a
dose of 1000mgm2 per day, on the expression of the ABCB1 and AMPK genes, when is added to
conventional induction remission chemotherapy in newly diagnosed adolescents with acute
lymphoblastic leukemia.